MOODY'S CORPORATION Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net
MOODY'S CORPORATION (MCO) reported Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net of $13.50 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-02.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet · last filed 2019-08-02
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2019-06-30 was $13.50M, a 542.86% increase year-over-year.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2019-03-31 was $8.30M.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2018-12-31 was $4.80M.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2018-09-30 was $4.10M.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2018 was $11.00M.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2013 was $0.00.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2012 was $0.00.
- MOODY'S CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2011 was $0.00.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month |
|---|---|---|---|---|
| 2019-06-30 | $13.50M 10-Q · filed 2019-08-02 | $21.80M 10-Q · filed 2019-08-02 | $26.60M derived: sum of 3 quarters · filed 2019-08-02 | $30.70M derived: sum of 4 quarters · filed 2019-08-02 |
| 2019-03-31 | $8.30M 10-Q · filed 2019-05-02 | $13.10M derived: sum of 2 quarters · filed 2019-05-02 | $17.20M derived: sum of 3 quarters · filed 2019-05-02 | $19.30M derived: sum of 4 quarters · filed 2019-08-02 |
| 2018-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $8.90M derived: sum of 2 quarters · filed 2019-02-25 | $11.00M derived: sum of 3 quarters · filed 2019-08-02 | $11.00M 10-K · filed 2019-02-25 |
| 2018-09-30 | $4.10M 10-Q · filed 2018-10-31 | $6.20M derived: sum of 2 quarters · filed 2019-08-02 | $6.20M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $2.10M 10-Q · filed 2019-08-02 | $2.10M 10-Q · filed 2019-08-02 | ||
| 2018-03-31 | -$500.00K 10-Q · filed 2018-05-01 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $400.00K derived: sum of 2 quarters · filed 2018-10-31 | $400.00K 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $400.00K 10-Q · filed 2017-07-27 | $400.00K 10-Q · filed 2017-07-27 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $0.00 derived: sum of 2 quarters · filed 2014-02-27 | $0.00 derived: sum of 3 quarters · filed 2014-02-27 | $0.00 10-K · filed 2014-02-27 |
| 2013-09-30 | $0.00 10-Q · filed 2013-10-31 | $0.00 derived: sum of 2 quarters · filed 2013-10-31 | $0.00 10-Q · filed 2013-10-31 | $0.00 derived: sum of 4 quarters · filed 2014-02-27 |
| 2013-06-30 | $0.00 10-Q · filed 2013-07-31 | $0.00 10-Q · filed 2013-07-31 | $0.00 derived: sum of 3 quarters · filed 2014-02-27 | $0.00 derived: sum of 4 quarters · filed 2014-02-27 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-03 | $0.00 derived: sum of 2 quarters · filed 2014-02-27 | $0.00 derived: sum of 3 quarters · filed 2014-02-27 | $0.00 derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $0.00 derived: sum of 2 quarters · filed 2014-02-27 | $0.00 derived: sum of 3 quarters · filed 2014-02-27 | $0.00 10-K · filed 2014-02-27 |
| 2012-09-30 | $0.00 10-Q · filed 2013-10-31 | $0.00 derived: sum of 2 quarters · filed 2013-10-31 | $0.00 10-Q · filed 2013-10-31 | |
| 2012-06-30 | $0.00 10-Q · filed 2013-07-31 | $0.00 10-Q · filed 2013-07-31 | ||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-03 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| S&P Global Inc. (SPGI) | United States | $119.368B | 26.35 |
| EQUIFAX INC (EFX) | United States | $17.483B | 26.99 |
| TransUnion (TRU) | United States | $13.027B | 18.94 |